Payment overview · 2025
General Payments
$268.36
19 reported records · 6 companies
Healthcare provider profile · identity verified
Lori D Fortner, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MOUNT IDA, AR · NPI 1982978532
Verified facts
What the public records show
CMS Open Payments records show Lori D Fortner, APRN received $268.36 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.72 | 58.8% | 14 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.95 | 9.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.64 | 9.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.05 | 8.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.53 | 7.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.47 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.36 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $109.85 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.92 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.91 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 191 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 44 |
| Lisinopril | Lisinopril | 127 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 33 |
| Omeprazole | Omeprazole | 99 | 30 |
| Tramadol Hcl | Tramadol Hcl | 99 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 97 | 34 |
| Losartan Potassium | Losartan Potassium | 94 | 25 |
| Meloxicam | Meloxicam | 84 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 79 | 32 |
| Eliquis | Apixaban | 75 | 21 |
| Potassium Chloride | Potassium Chloride | 75 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 38 |
| Clonazepam | Clonazepam | 61 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 20 |
| Prednisone | Prednisone | 55 | 43 |
| Trazodone Hcl | Trazodone Hcl | 55 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 22 |
| Furosemide | Furosemide | 49 | 18 |
| Simvastatin | Simvastatin | 48 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Famotidine | Famotidine | 42 | 17 |
| Azithromycin | Azithromycin | 40 | 34 |
| Carvedilol | Carvedilol | 40 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Lorazepam | Lorazepam | 37 | 16 |
| Metformin Hcl | Metformin Hcl | 37 | 15 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Cephalexin | Cephalexin | 15 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Glimepiride | Glimepiride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.36 · 19 records | ABBVIE INC. | BREZTRI, CAPLYTA, JOURNAVX, Ohtuvayre, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error